Skip to Content

Isavuconazonium Pregnancy and Breastfeeding Warnings

Isavuconazonium is also known as: Cresemba

Medically reviewed by Last updated on Jun 26, 2019.

Isavuconazonium Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

-Based on animal data, this drug may increase the risk of adverse developmental outcomes above background risk.
-Women who become pregnant while taking this drug should contact their physician.

Animal studies have revealed evidence of perinatal mortality and teratogenicity; dose-related increases in the incidences of rudimentary cervical ribs, zygomatic arch fusion, and supernumerary ribs/rudimentary supernumerary ribs observed. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Isavuconazonium Breastfeeding Warnings

Breastfeeding is not recommended during use of this drug.

Excreted into human milk: Data not available
Excreted into animal milk: Yes

See references

References for pregnancy information

  1. "Product Information. Cresemba (isavuconazonium)." Astellas Pharma US, Inc, Deerfield, IL.

References for breastfeeding information

  1. "Product Information. Cresemba (isavuconazonium)." Astellas Pharma US, Inc, Deerfield, IL.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.